Alchemia wins patents for generic fondaparinux
Wednesday, 25 June, 2008
Alchemia (ASX: ACL) has been granted patents for two of its family of the synthetic heparin oligosaccharides used in its fondaparinux synthesis production method.
Two of its other patent applications have been approved but not yet finalised.
The patents will grant legal protection to Alchemia's method of synthesising fondaparinux sodium up until the year 2022.
Alchemia, and its manufacturing partner Dr Reddy's, hope to go to market in 2009.
Fondaparinux is an anticoagulant medication,generally used subcutaneously daily, particularly in the treatment of deep-vain thrombosis and in those recovering from orthopaedic surgery.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
